Cart
sales@molnova.com
β-Amyrenonol
CAS No. 38242-02-3
β-Amyrenonol( ——— )
Catalog No. M39376 CAS No. 38242-02-3
β-Amyrenonol (11-Oxo-β-amyrin), an oleanolic-type triterpenoid in licorice roots, is a precursor of Glycyrrhetinic acid. β-Amyrenonol has anti-proliferative and anti-inflammatory activities, and β-Amyrenonol could function as the skeleton for the synthesis of many triterpenoids.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 504 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Nameβ-Amyrenonol
-
NoteResearch use only, not for human use.
-
Brief Descriptionβ-Amyrenonol (11-Oxo-β-amyrin), an oleanolic-type triterpenoid in licorice roots, is a precursor of Glycyrrhetinic acid. β-Amyrenonol has anti-proliferative and anti-inflammatory activities, and β-Amyrenonol could function as the skeleton for the synthesis of many triterpenoids.
-
DescriptionStandard reference
-
In Vitroβ-Amyrenonol (11-Oxo-β-amyrin) inhibits cell growth of HL60 cells with an IC50 value of 26.3 μM. β-Amyrenonol (11-Oxo-β-amyrin) (100 μM) significantly reduces lipopolysaccharide-induced TNFα release in THP-1 cells. CYP88D6 is characterized by in vitro enzymatic activity assays and shown to catalyze the sequential two-step oxidation of β-amyrin at C-11 to produce β-Amyrenonol (11-Oxo-β-amyrin). CYP88D6 coexpressed with β-amyrin synthase in yeast also catalyzed in vivo oxidation of β-amyrin to β-Amyrenonol.
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number38242-02-3
-
Formula Weight440.7
-
Molecular FormulaC30H48O2
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Atracurium besylate
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
-
Inbakicept
Inbakicept (ALT 803) is a fusion protein of the IL-15 receptor α-sushi binding domain IL-15RαSu and immunoglobulin G1 (human Fc fragment), which is an IL-15 superagonist protein complex.
-
LAH4
The a-helix of the amphipathic peptide antibiotic LAH4 (KKALLALALHHLAHLALHLALALKKA-NH2) strongly interacts with phospholipid membranes, demonstrating in vitro transfection efficiencies comparable to those of commercially available reagents.
